HOME >> BIOLOGY >> NEWS
Agreement to increase the flow of ideas from laboratory to clinic

The University of Manchester and pharmaceutical company AstraZeneca have signed an agreement to enhance each organisation's research into diseases such as cancer, inflammatory diseases and diabetes and obesity.

The agreement sets out how the University and AstraZeneca will work together to identify new ways to treat disease and to nurture and enhance discovery, pre-clinical and clinical research in a bid to better understand a variety of conditions. Under the agreement the University and AstraZeneca will exchange staff, share facilities and encourage joint ventures through long-term funded collaborations.

The parties will also focus on enabling technologies such as imaging, informatics and chemistry that have the potential to identify and accelerate drug discovery in a number of different disease areas.

The agreement formalises previous close contacts between the parties such as the appointment of Professor Hans Westerhoff as AstraZeneca Professor of Systems Biology and the development of collaborative science networks.

A key component of the agreement is the shared benefits that will accrue to the parties, including: the faster translation of high-impact science to the clinic and joint efforts to secure the UK science base.

An early example of the collaborative approach has been the establishment of a joint cancer alliance steering group focusing on translational science in the areas of cancer imaging, serological biomarkers of cancer and Phase I cancer clinical trials between AstraZeneca and the Manchester Cancer Research Centre. Early successes from this group include the establishment of a biomarkers network to share expertise between the two parties, a 1.25m project over three years focusing on serological markers of cancer; and pre-clinical and clinical fellowships in cancer imaging.

Professor Alan North, University of Manchester Vice-President and Dean of the Faculty of Life Sciences, said: "Te
'"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
11-Jul-2006


Page: 1 2 3

Related biology news :

1. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study
2. Gene variant increases risk of blindness
3. Study finds Western-style meat-sweet diet increases risk of breast cancer in postmenopausal women
4. Gene variations directly link inflammation to an increased risk for lung cancer
5. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
6. Endometriosis increases the risk of certain cancers
7. Gene variant increases risk for alcoholism following childhood abuse
8. Does stimulant treatment for ADHD increase risk of drug abuse?
9. BRCA2 carriers at increased risk for deadly form of prostate cancer
10. Salvage logging, replanting increased biscuit fire severity
11. A first: Simultaneous PET/MR images of the brain debut, increase molecular imaging capabilities

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
(Date:6/28/2020)... , ... June 25, 2020 ... ... enterprise software solutions for biopharmaceutical R&D, today announced that it has entered ... innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and clinical research ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of innovative ... to support testing operations in the fight against the COVID-19 pandemic in Zambia. ...
Breaking Biology News(10 mins):
(Date:5/21/2020)... ... May 19, 2020 , ... Experienced periodontist in Eden Prairie, MN, Dr. ... bone grafting through PIEZOSURGERY® technology. PIEZOSURGERY uses ultrasonic vibrations to gently cut ... a patient for dental implants, especially when the implants need to be placed in ...
(Date:5/21/2020)... (PRWEB) , ... May 20, 2020 , ... ... addition of Simon Prakash, who will serve as the company’s executive vice president ... a time when Exo is disrupting the medical imaging space, bringing more than ...
(Date:5/15/2020)... ... May 14, 2020 , ... Children with defective heart valves ... before becoming adults. The reason: there are no heart valve prosthetics designed to ... Department of Defense has awarded Draper, Boston Children’s Hospital and Seattle Children’s Research ...
(Date:5/15/2020)... LEXINGTON, Mass. (PRWEB) , ... May 15, 2020 , ... ... announced the appointment of Richard Ganz as Executive Chairman. Mr. Ganz will continue ... nine years, as well as work closely with CEO Brian Miller and Sentien’s management ...
Breaking Biology Technology:
Cached News: